Abstract | PURPOSE: Patients with American Joint Committee on Cancer (AJCC) stage III melanoma are at high risk of recurrence and death. We hypothesized that a multiple-marker reverse transcriptase polymerase chain reaction (MM-RT-PCR) blood assay could predict, early in the course of therapy, those patients destined to experience treatment failure with a melanoma vaccine (MV) previously shown to improve survival in a phase II clinical trial. PATIENTS AND METHODS: After complete surgical resection, prospectively collected cryopreserved peripheral-blood lymphocyte specimens (n = 90) from the serial bleeds of 30 patients with AJCC stage III melanoma were studied by MM-RT-PCR, using the markers tyrosinase, melanoma antigen recognized by T cells-1 (MART-1), and universal melanoma antigen gene-A (uMAG-A). All patients were enrolled in a phase II MV trial during the period of blood draws, and were selected for this study in a blinded fashion. Median duration of clinical follow-up was 74 months for the 13 survivors and 11 months for the 17 nonsurvivors. RESULTS: The presence of at least one melanoma-specific RT-PCR marker was associated with an increased risk of disease recurrence (risk rate, 3.12; P =.02) and decreased risk of survival (relative rate, 2.62; P =.0496) by multivariate analysis. CONCLUSION: MM-RT-PCR of the blood provided early prediction of subsequent disease recurrence and death in clinically disease-free AJCC stage III melanoma patients enrolled in a MV phase II trial. On the basis of the results of this pilot study, the MM-RT-PCR blood assay should be considered as a clinically important monitoring tool for assessing patient response to adjuvant therapy, and in the surveillance of clinically disease-free patients for the earliest signs of recurrence.
|
Authors | Robert A Wascher, Donald L Morton, Christine Kuo, Robert M Elashoff, He-Jing Wang, Mehri Gerami, Dave S B Hoon |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 21
Issue 13
Pg. 2558-63
(Jul 01 2003)
ISSN: 0732-183X [Print] United States |
PMID | 12829676
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antigens, Neoplasm
- Biomarkers, Tumor
- Cancer Vaccines
- MART-1 Antigen
- MLANA protein, human
- Neoplasm Proteins
- Monophenol Monooxygenase
|
Topics |
- Adult
- Aged
- Antigens, Neoplasm
(analysis)
- Biomarkers, Tumor
(analysis)
- Cancer Vaccines
(immunology, pharmacology)
- Female
- Humans
- MART-1 Antigen
- Male
- Melanoma
(immunology, pathology)
- Middle Aged
- Monophenol Monooxygenase
(analysis)
- Multivariate Analysis
- Neoplasm Proteins
(analysis)
- Neoplasm Recurrence, Local
- Predictive Value of Tests
- Reverse Transcriptase Polymerase Chain Reaction
- Risk Factors
- Skin Neoplasms
(immunology, pathology)
- Survival
- Treatment Outcome
|